Document ID: chunk:federal_register_of_legislation:F2024C01086:clause:1_14219
Version: federal_register_of_legislation:F2024C01086
Segment Type: clause
Provision Reference: sch 1 cl 14219
Character Range: 888941–891716

14219                                                                                               Professional attendance on a patient by a psychiatrist, who has undertaken training in Repetitive Transcranial Magnetic Stimulation (rTMS), for treatment mapping for rTMS, if the patient:                                                                                                                                                                                                                                                                                                                                                                                                                               186.40
                                                                                                    (a) is at least 18 years old; and
                                                                                                    (b) is diagnosed with a major depressive episode; and
                                                                                                    (c) has failed to receive satisfactory improvement for the major depressive episode despite the adequate trialling of at least 2 different classes of antidepressant medications, unless contraindicated, and all of the following apply:
                                                                                                    (i) the patient's adherence to antidepressant treatment has been formally assessed;
                                                                                                    (ii) the trialling of each antidepressant medication has been at the recommended therapeutic dose for a minimum of 3 weeks;
                                                                                                    (iii) where clinically appropriate, the treatment has been titrated to the maximum tolerated therapeutic dose; and
                                                                                                    (d) has undertaken psychological therapy, if clinically appropriate; and
                                                                                                    (e) has previously received an initial service under item 14217 and the patient:
                                                                                                    (i) has relapsed after a remission following the initial service; and
                                                                                                    (ii) has had a satisfactory clinical response to the service under item 14217 (which has been assessed by a validated major depressive disorder tool at least 4 months after receiving that service)